Back to top
more

Innoviva (INVA)

(Real Time Quote from BATS)

$20.15 USD

20.15
168,912

-0.03 (-0.15%)

Updated Nov 11, 2024 02:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe

by Zacks Equity Research

Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.

Moving Average Crossover Alert: Innoviva (INVA)

by Zacks Equity Research

Innoviva, Inc. (INVA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

Theravance Up as CHMP Backs Trelegy Elipta Line Extension

by Zacks Equity Research

Theravance Biopharma (TBPH) highlights positive CHMP opinion supporting label expansion of Glaxo's COPD drug, Trelegy Elipta. Theravance has economic interest in the drug and earns royalties on its sales.

    AstraZeneca's Bevespi Unimpressive in Phase III COPD Study

    by Zacks Equity Research

    AstraZeneca's (AZN) inhaler, Bevespi Aerosphere, fails to demonstrate superiority over Glaxo's Arono in a phase III COPD study.

      Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan

      by Zacks Equity Research

      Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.

        AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III

        by Zacks Equity Research

        AstraZeneca (AZN) announces positive top-line results from the phase III KRONOS study on the triple combination therapy PT010 for severe COPD patients.

          Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler

          by Zacks Equity Research

          Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.

            Theravance Shares Rise on Approval of Glaxo's COPD Therapy

            by Zacks Equity Research

            Theravance Biopharma's (TBPH) shares traded up as investors cheered the potential cash flows related to future sales of recently approved Glaxo's triple combination COPD therapy.

              Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU

              by Zacks Equity Research

              Glaxo (GSK) and partner Innoviva announced that their triple combination therapy, Trelegy Ellipta, was granted marketing authorization in the EU as maintenance therapy for the treatment of patients with COPD.

                AstraZeneca's Bevespi Improves Lung Function in Phase III Study

                by Zacks Equity Research

                AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.

                  Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III

                  by Zacks Equity Research

                  GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.

                    Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD

                    by Zacks Equity Research

                    The FDA approves GlaxoSmithKline (GSK) and Innoviva's triple combination therapy, FF/UMEC/VI, for COPD. The drug will be accessed as Trelegy Ellipta in the U.S. market.

                      Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU

                      by Zacks Equity Research

                      Glaxo's (GSK) single inhaler triple therapy for the treatment of COPD in patients who are already being treated with a ICS/LAMA combination received a positive opinion from the CHMP in the EU.

                        Illumina (ILMN) Catches Eye: Stock Soars 14.8%

                        by Zacks Equity Research

                        Illumina (ILMN) was a big mover last session, as the company saw its shares rise over 14% on the day.

                          Moving Average Crossover Alert: Innoviva (INVA)

                          by Zacks Equity Research

                          Innoviva, Inc. (INVA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

                            Can The Uptrend Continue for Innoviva (INVA)?

                            by Zacks Equity Research

                            Investors certainly have to be happy with Innoviva, Inc. (INVA) and its short term performance